Nektar Therapeutics’s Collaboration agreement with Bristol-Myers Squibb

Sidley advised Nektar Therapeutics (Nasdaq:NKTR) on a global strategic development and commercialization collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for Nektar’s CD122-biased agonist, NKTR-214. Bristol-Myers Squibb Company…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now